(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 39.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Opus Genetics's revenue in 2025 is $15,421,000.On average, 1 Wall Street analysts forecast IRD's revenue for 2025 to be $914,796,000, with the lowest IRD revenue forecast at $914,796,000, and the highest IRD revenue forecast at $914,796,000. On average, 1 Wall Street analysts forecast IRD's revenue for 2026 to be $1,519,268,275, with the lowest IRD revenue forecast at $1,519,268,275, and the highest IRD revenue forecast at $1,519,268,275.
In 2027, IRD is forecast to generate $2,570,654,640 in revenue, with the lowest revenue forecast at $2,570,654,640 and the highest revenue forecast at $2,570,654,640.